Biomea Fusion, Inc. Biomea to present preclinical data from multiple in vivo studies Biomea plans to initiate a Phase I/II clinical trial of BMF-219 in diabetes in the second half…
Tag: Biomea
Biomea Fusion Releases Pre-Clinical Data with BMF-219 in Diabetes
REDWOOD CITY, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of irreversible small molecules to…